Literature DB >> 22376134

Single arc volumetric modulated arc therapy for complex brain gliomas: is there an advantage as compared to intensity modulated radiotherapy or by adding a partial arc?

M T M Davidson1, G L Masucci, M Follwell, S J Blake, W Xu, D J Moseley, P Sanghera, C S Wong, J Perry, M Tsao, A Sahgal.   

Abstract

The objective of this study was to determine if volumetric modulated arc therapy (VMAT) offers advantages over intensity modulated radiotherapy (IMRT) for complex brain gliomas and evaluate the role of an additional partial arc. Twelve patients with glioma involving critical organs at risk (OAR) were selected [six low grade brainstem glioma (BG) and six glioblastoma (GB) cases]. BGs were prescribed 54 Gy/30 fractions (frx), and GB treated to 50 Gy/30 frx to a lower dose PTV (PTV50) with a simultaneous integrated boost delivering a total dose of 60 Gy/30 frx to a higher dose PTV (PTV60). VMAT was planned with a single arc (VMAT1) and with an additional coplanar partial arc spanning 90° (VMAT2). We observed VMATI improving the PTV equivalent uniform dose (EUD) for BG cases (p=0.027), improving the V95 for the PTV50 in GB cases (p=0.026) and resulting in more conformal GB plans (p=0.008) as compare to IMRT. However, for the GB PTV60, IMRT achieved favorable V95 over VMAT1 and VMAT2 (0.0046 and 0.008, respectively). The GB total integral dose (ID) was significantly lower with VMAT1 and VMAT2 (p=0.049 and p=0.006, respectively). Both VMAT1 and VMAT2 reduced the ID, however, only at the 5 Gy threshold for BG cases (p=0.011 and 0.005, respectively). VMAT achieved a lower spinal cord maximum dose and EUD for BG cases and higher optic nerve doses, otherwise no significant differences were observed. VMAT1 yielded the fastest treatment times and least MU. We conclude that VMAT offers faster treatment delivery for complex brain tumors while maintaining similar dosimetric qualities to IMRT. Selective dosimetric advantages in terms of spinal cord sparing and lowering the ID are observed favoring the use of an additional coplanar partial arc.

Entities:  

Mesh:

Year:  2012        PMID: 22376134     DOI: 10.7785/tcrt.2012.500289

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  6 in total

1.  Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.

Authors:  J Sherriff; J Tamangani; L Senthil; G Cruickshank; D Spooner; B Jones; C Brookes; P Sanghera
Journal:  Br J Radiol       Date:  2013-02       Impact factor: 3.039

2.  Feasibility of extreme dose escalation for glioblastoma multiforme using 4π radiotherapy.

Authors:  Dan Nguyen; Jean-Claude M Rwigema; Victoria Y Yu; Tania Kaprealian; Patrick Kupelian; Michael Selch; Percy Lee; Daniel A Low; Ke Sheng
Journal:  Radiat Oncol       Date:  2014-11-07       Impact factor: 3.481

Review 3.  Special stereotactic radiotherapy techniques: procedures and equipment for treatment simulation and dose delivery.

Authors:  Lisa Paoletti; Corrado Ceccarelli; Claudia Menichelli; Cynthia Aristei; Simona Borghesi; Enrico Tucci; Paolo Bastiani; Salvatore Cozzi
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

4.  Comparison of Prospectively Generated Glioma Treatment Plans Clinically Delivered on Magnetic Resonance Imaging (MRI)-Linear Accelerator (MR-Linac) Versus Conventional Linac: Predicted and Measured Skin Dose.

Authors:  Michael H Wang; Anthony Kim; Mark Ruschin; Hendrick Tan; Hany Soliman; Sten Myrehaug; Jay Detsky; Zain Husain; Eshetu G Atenafu; Brian Keller; Arjun Sahgal; Chia-Lin Tseng
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 5.  Clinical utility of RapidArc™ radiotherapy technology.

Authors:  Erminia Infusino
Journal:  Cancer Manag Res       Date:  2015-11-12       Impact factor: 3.989

6.  Intensity Modulated Radiation Therapy Versus Volumetric Arc Radiation Therapy in the Treatment of Glioblastoma-Does Clinical Benefit Follow Dosimetric Advantage?

Authors:  Tommy Sheu; Tina M Briere; Adenike M Olanrewaju; Mary Frances McAleer
Journal:  Adv Radiat Oncol       Date:  2018-09-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.